Lepu Biopharma Co Ltd
HKEX:2157
Intrinsic Value
Lepu Biopharma Co., Ltd. operates as an an innovation-driven biopharmaceutical company. [ Read More ]
The intrinsic value of one Lepu Biopharma Co Ltd stock under the Base Case scenario is 2.06 HKD. Compared to the current market price of 4.7 HKD, Lepu Biopharma Co Ltd is Overvalued by 56%.
Valuation Backtest
Lepu Biopharma Co Ltd
Run backtest to discover the historical profit from buying and selling Lepu Biopharma Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Lepu Biopharma Co Ltd
| Current Assets | 677.1m |
| Cash & Short-Term Investments | 489.6m |
| Receivables | 158.1m |
| Other Current Assets | 29.4m |
| Non-Current Assets | 1.7B |
| Long-Term Investments | 126.7m |
| PP&E | 1.1B |
| Intangibles | 434.2m |
| Other Non-Current Assets | 59m |
| Current Liabilities | 899.6m |
| Accounts Payable | 207.6m |
| Other Current Liabilities | 692m |
| Non-Current Liabilities | 587.8m |
| Long-Term Debt | 284.2m |
| Other Non-Current Liabilities | 303.7m |
Earnings Waterfall
Lepu Biopharma Co Ltd
|
Revenue
|
225.4m
CNY
|
|
Cost of Revenue
|
-28.3m
CNY
|
|
Gross Profit
|
197.1m
CNY
|
|
Operating Expenses
|
-412.5m
CNY
|
|
Operating Income
|
-215.5m
CNY
|
|
Other Expenses
|
193.4m
CNY
|
|
Net Income
|
-22.1m
CNY
|
Free Cash Flow Analysis
Lepu Biopharma Co Ltd
Profitability Score
Profitability Due Diligence
Lepu Biopharma Co Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
Lepu Biopharma Co Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Lepu Biopharma Co Ltd's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Score
Lepu Biopharma Co Ltd's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Lepu Biopharma Co Ltd
According to Wall Street analysts, the average 1-year price target for Lepu Biopharma Co Ltd is 3.77 HKD with a low forecast of 3.74 HKD and a high forecast of 3.89 HKD.
Shareholder Return
Price
Lepu Biopharma Co Ltd
| Average Annual Return | 4.9% |
| Standard Deviation of Annual Returns |
N/A
|
| Max Drawdown | -89% |
| Market Capitalization | 7.8B HKD |
| Shares Outstanding | 1 659 444 840 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Lepu Biopharma Co., Ltd. operates as an an innovation-driven biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2022-02-23. The firm mainly develops product lines of tumor candidate drugs, including antibody drug conjugate (ADC), oncolytic virus drug products and immunotherapy at clinical and pre-clinical stages. The Company’s major pipeline assets consist of MRG003, MRG002, HX008 and LP002, and three key clinical-stage drug candidates. The firm's products are sold at home and abroad.
Contact
IPO
Employees
Officers
The intrinsic value of one Lepu Biopharma Co Ltd stock under the Base Case scenario is 2.06 HKD.
Compared to the current market price of 4.7 HKD, Lepu Biopharma Co Ltd is Overvalued by 56%.
You don't have any saved screeners yet
